SEMINAL PRESENTATION OF FIRST ANALYTICAL VALIDATION DATA SCHEDULED FOR JUNE 30 TURKU, Finland, June 27, 2022 /PRNewswire/ Genomill, a precision diagnostics company focused on
/PRNewswire/ Genomill, a precision diagnostics company focused on maximizing next generation sequencing (NGS) in liquid biopsies, announces today that Mike.
(2)
These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021.
Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally.
Regulatory News:
Thomas Bonnefont (Photo: Median Technologies)
Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy Business Unit as well as the appointment of Mike Doherty as Sr. Strategy Advisor, iBiopsy Product Development. They both join Median s executive team. Mike Doherty is based in the US.